Literature DB >> 25941597

Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Lorenzo Galluzzi1, Guido Kroemer2, Alexander Eggermont3.   

Abstract

Entities:  

Keywords:  CTLA4; CTLA4, cytotoxic T lymphocyte-associate protein 4; FDA, Food and Drug Administration; Keytruda™; PD-1; PDCD1/PD-1, programmed cell death 1; Yervoy™; ipilimumab; nivolumab

Year:  2014        PMID： 25941597      PMCID： PMC4292712          DOI： 10.4161/21624011.2014.967147

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  93 in total

1.  Anti-CTLA4 antibody-induced lupus nephritis.

Authors:  Fouad Fadel; Khalil El Karoui; Bertrand Knebelmann
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

2.  Immunity unleashed in melanoma.

Authors:  Michael K Erdmann
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

3.  Treatment of advanced melanoma with immunological checkpoint block.

Authors:  Kim Margolin
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

Review 4.  Trial Watch: Radioimmunotherapy for oncological indications.

Authors:  Norma Bloy; Jonathan Pol; Gwenola Manic; Ilio Vitale; Alexander Eggermont; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

5.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 7.  Trial Watch: Anticancer radioimmunotherapy.

Authors:  Erika Vacchelli; Ilio Vitale; Eric Tartour; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

8.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

Review 9.  Trial Watch: DNA vaccines for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-04-01       Impact factor: 8.110

Review 10.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-05-01       Impact factor: 8.110
View more
  19 in total

1.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

Review 2.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 3.  Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Authors:  Jonathan Pol; Erika Vacchelli; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

4.  Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

5.  Doubling the blockade for melanoma immunotherapy.

Authors:  Lorenzo Galluzzi; Alexander Eggermont; Guido Kroemer
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

6.  Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.

Authors:  Sylvain Ladoire; Laura Senovilla; David Enot; François Ghiringhelli; Vichnou Poirier-Colame; Kariman Chaba; Gulsun Erdag; Jochen T Schaefer; Donna H Deacon; Laurence Zitvogel; Craig L Slingluff; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 7.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 8.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 9.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 10.  Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Authors:  Kristina Iribarren; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Špíšek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-09-02       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.